Lunit , a leading provider of AI for cancer diagnostics and therapeutics, announced that Volpara Health Technologies will now operate under the Lunit brand, introducing a unified global identity that merges their complementary strengths in breast health and AI innovation.
This milestone builds on Lunit’s 2024 acquisition of Volpara, an important step that aligned both companies under one vision: to conquer cancer through AI.
The integration builds a comprehensive ecosystem spanning risk prediction, early detection, imaging quality, and data-driven precision medicine, delivering greater value for clinicians, researchers, and patients worldwide. This positions Lunit among the few AI healthcare companies with a comprehensive cancer intelligence portfolio—from breast health and screening to precision oncology—serving over 10,000 healthcare providers across more than 65 countries.
“By bringing Volpara under the Lunit brand, we’re uniting our technologies, teams, and mission to deliver a connected ecosystem that transforms how cancer is detected and treated worldwide,” said Brandon Suh, CEO of Lunit. “This marks the start of a new era of collaboration and impact across every stage of cancer care.”
To accelerate and enhance regional growth, Lunit is evolving its global operations under a unified structure. Lunit International (formerly Volpara Health Technologies) encompassing all former Volpara operations across the U.S., Oceania, Europe, and Asia, will lead Lunit’s business development and customer engagement efforts in these markets.
In parallel, Lunit is transitioning part of its global sales organization into these regional hubs, allowing the Seoul headquarters to focus on AI research, innovation, and new product development—further sharpening its global focus and specialization.
As part of this milestone, Lunit has launched a newly designed website , reflecting its new digital identity and serving as a single digital gateway to its AI solutions, research, and corporate resources.
“Our mission remains the same,” added Suh. “We aim to make AI the new standard for the entire cancer journey. We want every patient, regardless of geography or resources, to benefit from the same level of precision and insight, ensuring equitable access to life-saving diagnostics worldwide.”
Health Technology Insights: FDA Approves Interchangeable Status for Fresenius Kabi Biosimilars
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
